Phase 2 AMG 714 in Rheumatoid Arthritis

This study has been completed.
Information provided by:
Amgen Identifier:
First received: February 8, 2007
Last updated: December 20, 2007
Last verified: December 2007

Twelve week treatment of AMG 714 in RA patients who failed at least one DMARD, followed by a 3 month observational period.

Condition Intervention Phase
Rheumatoid Arthritis
Drug: AMG 714
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo Controlled, Randomized, Parallel-Group Clinical Trial With Multiple Dose Treatment of Anti-IL 15 Human Monoclonal Antibody (AMG 714) in Patients With Active Rheumatoid Arthritis Who Have Previously Failed One or More Disease Modifying Anti-Rheumatic Drugs

Resource links provided by NLM:

Further study details as provided by Amgen:

Estimated Enrollment: 180
Study Start Date: December 2002

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both

Inclusion Criteria: Diagnosis of RA -

Exclusion Criteria: No prior biologic treatment for RA


  Contacts and Locations
Please refer to this study by its identifier: NCT00433875

Sponsors and Collaborators
Study Director: MD Amgen
  More Information

Additional Information:
No publications provided

Responsible Party: Global Development Leader, Amgen Inc. Identifier: NCT00433875     History of Changes
Other Study ID Numbers: 20030210
Study First Received: February 8, 2007
Last Updated: December 20, 2007
Health Authority: Denmark: Ministry of Health
Germany: Federal Institute for Drugs and Medical Devices
Poland: Drug Institut
South Africa: Department of Health
Sweden: Medical Products Agency
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Antirheumatic Agents
Therapeutic Uses
Pharmacologic Actions processed this record on April 23, 2014